NO20052575L - Nye forbindelser, deres fremstilling og anvendelse - Google Patents

Nye forbindelser, deres fremstilling og anvendelse

Info

Publication number
NO20052575L
NO20052575L NO20052575A NO20052575A NO20052575L NO 20052575 L NO20052575 L NO 20052575L NO 20052575 A NO20052575 A NO 20052575A NO 20052575 A NO20052575 A NO 20052575A NO 20052575 L NO20052575 L NO 20052575L
Authority
NO
Norway
Prior art keywords
compounds
preparation
new compounds
compositions
treatment
Prior art date
Application number
NO20052575A
Other languages
English (en)
Inventor
Lone Jeppesen
Per Sauerberg
Ingrid Pettersson
John Patrick Mogensen
Pavel Pihera
Miroslav Havranek
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20052575L publication Critical patent/NO20052575L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708Ethers
    • C07C69/712Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40Radicals substituted by oxygen atoms
    • C07D307/42Singly bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Semiconductor Memories (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Optical Integrated Circuits (AREA)

Abstract

Nye forbindelser med den generelle formel (I) anvendelsen av disse forbindelsene som farmasøytiske preparater, farmasøytiske preparater som omfatter forbindelsene, og fremgangsmåter for behandling ved anvendelse av disse forbindelsene og preparatene. De foreliggende forbindelser kan være anvendbare ved behandlingen og/eUer profylaksen av tilstander mediert av peroksisomproUferatoraktiverte reseptorer (PPAR), særlig PPARS-undertypen.
NO20052575A 2002-10-28 2005-05-27 Nye forbindelser, deres fremstilling og anvendelse NO20052575L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201631 2002-10-28
DKPA200300793 2003-05-26
PCT/DK2003/000722 WO2004037776A2 (en) 2002-10-28 2003-10-27 Novel compounds and their use as prar-modulators

Publications (1)

Publication Number Publication Date
NO20052575L true NO20052575L (no) 2005-05-27

Family

ID=32178576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052575A NO20052575L (no) 2002-10-28 2005-05-27 Nye forbindelser, deres fremstilling og anvendelse

Country Status (15)

Country Link
EP (1) EP1558572B1 (no)
JP (1) JP4708184B2 (no)
KR (1) KR20050061562A (no)
AT (1) ATE472526T1 (no)
AU (2) AU2003273783C1 (no)
BR (1) BR0315683A (no)
CA (1) CA2503280A1 (no)
DE (1) DE60333211D1 (no)
ES (1) ES2345882T3 (no)
MX (1) MXPA05004402A (no)
NO (1) NO20052575L (no)
PL (1) PL376718A1 (no)
RU (1) RU2349582C2 (no)
WO (1) WO2004037776A2 (no)
ZA (1) ZA200502814B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129268B2 (en) * 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
AU2004283147A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
BRPI0510024A (pt) * 2004-05-14 2007-09-25 Irm Llc compostos e composições como modulares de ppar
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US20100197950A1 (en) * 2006-06-08 2010-08-05 Kaare Gyberg Rasmussen Process for preparing phenoxy acetic acid derivatives
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
EP4061356A4 (en) * 2019-11-19 2024-03-20 NIBN, The National Institute for Biotechnology in the Negev Ltd. NOVEL BENZOTHIOPHENE DERIVATIVES AND THEIR USE TO STIMULATE MITOCHONDRIAL RENEWAL
AU2021312855A1 (en) 2020-07-22 2023-03-09 Reneo Pharmaceuticals, Inc. Crystalline PPAR-delta agonist
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262334T1 (de) 1996-02-02 2004-04-15 Merck & Co Inc Antidiabetisches mittel
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
US5773469A (en) 1996-06-18 1998-06-30 Ortho Pharmaceutical Corporation Diaryl antimicrobial agents
WO1998027974A1 (en) 1996-12-23 1998-07-02 Merck & Co., Inc. Antidiabetic agents
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
KR20020005703A (ko) * 1999-04-20 2002-01-17 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 신규한 화합물, 그의 제법 및 용도
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001354671A (ja) 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
BR0211414A (pt) * 2001-07-30 2004-08-17 Novo Nordisk As Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas

Also Published As

Publication number Publication date
MXPA05004402A (es) 2005-07-26
JP2006503908A (ja) 2006-02-02
RU2349582C2 (ru) 2009-03-20
PL376718A1 (pl) 2006-01-09
AU2003273783B2 (en) 2010-03-18
EP1558572A2 (en) 2005-08-03
ZA200502814B (en) 2005-12-28
BR0315683A (pt) 2005-08-30
WO2004037776A3 (en) 2004-06-10
DE60333211D1 (de) 2010-08-12
EP1558572B1 (en) 2010-06-30
ES2345882T3 (es) 2010-10-05
KR20050061562A (ko) 2005-06-22
JP4708184B2 (ja) 2011-06-22
AU2010201560A1 (en) 2010-05-06
CA2503280A1 (en) 2004-05-06
AU2003273783C1 (en) 2010-08-12
ATE472526T1 (de) 2010-07-15
AU2003273783A1 (en) 2004-05-13
WO2004037776A2 (en) 2004-05-06
RU2005116243A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
NO20033181L (no) Substituerte alkylaminderivater og fremgangsmåter for anvendelse
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
DK1392282T3 (da) Dermatologiske og kosmetiske sammensætninger, der omfatter et furfurylderivat
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
MY138906A (en) Phenyl derivatives as ppar agonists
SE0403006D0 (sv) New compounds
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20084328L (no) Nye forbindelser
ATE384058T1 (de) Thiazolderivate
EA200870103A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
NO20052575L (no) Nye forbindelser, deres fremstilling og anvendelse
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20071005L (no) Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
CY1106973T1 (el) Παραγωγα θειαζολινης ως εκλεκτικοι διαμορφωται υποδοχεως ανδρογονου (sarms)
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
HRP20050103A2 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
PL376704A1 (pl) Nowe związki przydatne w leczeniu chorób, w których pośredniczy PPAR
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application